News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cancer and Leukemia Group B Release: Data from Phase II Clinical Trial of Galiximab in Combination with Rituximab in Patients with Previously Untreated Follicular Lymphoma Presented at International Conference on Malignant Lymphoma


6/9/2008 8:56:34 AM

LUGANO, Switzerland--(BUSINESS WIRE)--The Cancer and Leukemia Group B (CALGB) today announced data from a phase II clinical trial showing that 70 percent of patients with previously untreated follicular lymphoma responded to treatment with galiximab, an investigational anti-CD80 monoclonal antibody, when given in combination with rituximab. Of the 61 patients in the study, 44 percent achieved a complete response and 26 percent had a partial response. The data were presented at the 10th International Conference on Malignant Lymphoma (ICML).

Read at BioSpace.com

Related News

comments powered by Disqus
   
Lymphoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES